These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32685589)

  • 21. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease.
    Rizio AA; Bhor M; Lin X; McCausland KL; White MK; Paulose J; Nandal S; Halloway RI; Bronté-Hall L
    Qual Life Res; 2020 Jun; 29(6):1533-1547. PubMed ID: 31933113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
    Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
    JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.
    Ramsey SD; Bender MA; Li L; Johnson KM; Jiao B; Devine B; Basu A
    PLoS One; 2022; 17(11):e0278137. PubMed ID: 36445914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center.
    Barros GDS; Leal CVF; Leite LAC; Fujimoto DE; Cançado RD
    Hematol Transfus Cell Ther; 2024; 46(2):161-166. PubMed ID: 38307824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
    Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
    PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort.
    Strunk C; Tartaglione I; Piccone CM; Colombatti R; Andemariam B; Manwani D; Smith A; Haile H; Kim E; Wilson S; Asare EV; Rivers A; Farooq F; Urbonya R; Boruchov D; Boatemaa GD; Perrotta S; Ekem I; Sainati L; Rao S; Zempsky W; Sey F; Antwi-Boasiako C; Segbefia C; Inusa B; Campbell AD
    Blood Cells Mol Dis; 2021 Dec; 92():102612. PubMed ID: 34564050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
    Alkhalifah SA; Alanazi M; Almasaoud MA; Al-Malki HS; Al-Murdhi FM; Al-Hazzaa MS; Al-Mufarrij SM; Albabtain MA; Alshiakh AA; AlRuthia Y
    BMC Emerg Med; 2022 Nov; 22(1):188. PubMed ID: 36447134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis.
    Manwani D; Burnett AL; Paulose J; Yen GP; Burton T; Anderson A; Wang S; Lee S; Saraf SL
    EJHaem; 2022 Nov; 3(4):1135-1144. PubMed ID: 36467832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
    Beillat M; Durand-Zaleski I; Pirenne F; Bénard S; Chillotti L; Galacteros F
    Front Public Health; 2023; 11():1215605. PubMed ID: 37808997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hospitalist management of vaso-occlusive pain crisis in patients with sickle cell disease using a pathway of care.
    Allen Liles E; Kirsch J; Gilchrist M; Adem M
    Hosp Pract (1995); 2014 Apr; 42(2):70-6. PubMed ID: 24769786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare utilization and the quality of life of children and adolescents with sickle cell disease.
    Moody KL
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29685. PubMed ID: 35373909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees.
    Mahesri M; Schneeweiss S; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Desai RJ
    Eur J Haematol; 2021 Feb; 106(2):273-280. PubMed ID: 33155319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.
    Jordan L; Adams-Graves P; Kanter-Washko J; Oneal PA; Sasane M; Vekeman F; Bieri C; Magestro M; Marcellari A; Duh MS
    Curr Med Res Opin; 2015 Mar; 31(3):513-23. PubMed ID: 25495135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
    Bou-Maroun LM; Meta F; Hanba CJ; Campbell AD; Yanik GA
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28801954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of opioid use in sickle cell disease.
    Han J; Zhou J; Saraf SL; Gordeuk VR; Calip GS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):479-486. PubMed ID: 28815799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infrequent Resolution of Vaso-Occlusive Crises in Routine Clinical Care Among Patients Mimicking the Exa-Cel Trial Population: A Cohort Study of Medicaid Enrollees.
    Mahesri M; Lee SB; Levin R; Imren S; Zhang L; Beukelman T; Titievsky L; Desai RJ
    Clin Pharmacol Ther; 2024 Dec; 116(6):1572-1579. PubMed ID: 39328080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD.
    Yu T; Campbell T; Ciuffetelli I; Haywood C; Carroll CP; Resar L; Strouse JJ; Lanzkron S
    South Med J; 2016 Sep; 109(9):519-24. PubMed ID: 27598353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost.
    Peterson EE; Salemi JL; Dongarwar D; Salihu HM
    Eur J Pediatr; 2020 Nov; 179(11):1701-1710. PubMed ID: 32394268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.